Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Telitacicept,Inapplicable
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : RA Capital Management
Deal Size : $175.0 million
Deal Type : Private Placement
Vor Bio Announces $175 Million Private Placement
Details : The proceeds will be used to fund the clinical development of Vor Bio pipeline, which includes RC18 (telitacicept), a novel, dual-target recombinant fusion protein.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
June 25, 2025
Lead Product(s) : Telitacicept,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : RA Capital Management
Deal Size : $175.0 million
Deal Type : Private Placement
Lead Product(s) : Telitacicept,Inapplicable
Therapeutic Area : Immunology
Study Phase : Phase III
Recipient : RemeGen
Deal Size : $4,125.0 million
Deal Type : Licensing Agreement
Vor Bio Enters into Exclusive Global License Agreement with RemeGen
Details : Vor Bio receives ex-Greater China rights to develop and commercialize RC18 (telitacicept), a novel, dual-target recombinant fusion protein in global Phase 3 for generalized myasthenia gravis.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : $45.0 million
June 25, 2025
Lead Product(s) : Telitacicept,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : Phase III
Recipient : RemeGen
Deal Size : $4,125.0 million
Deal Type : Licensing Agreement
Lead Product(s) : VCAR33,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $55.6 million
Deal Type : Private Placement
Vor Bio Announces $55.6 Million Private Placement
Details : Vor Bio will use the net proceeds to fund the clinical and preclinical development of its pipeline candidates, including VCAR33, which is being evaluated for the treatment of relapsed/refractory AML.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
December 27, 2024
Lead Product(s) : VCAR33,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $55.6 million
Deal Type : Private Placement
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vor Bio Shares Clinical Update on Shielded Transplants and FDA Support for Trial Design
Details : VOR33 (trem-cel) followed by Mylotarg is being investigated in patients with relapsed/refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VCAR33,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Update
Details : VCAR33 is a CD33-directed CAR-T cell therapy made from healthy donor cells, under phase 1/2 development for treating relapsed/refractory acute myeloid leukemia.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 17, 2024
Lead Product(s) : VCAR33,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VCAR33,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
August 09, 2023
Lead Product(s) : VCAR33,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trem-cel (tremtelectogene empogeditemcel), is a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate in order to remove the CD33 surface target protecting them from a targeted therapy post-transplant.
Product Name : Trem-cel
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 16, 2023
Lead Product(s) : Tremtelectogene Empogeditemcel,Ozogamicin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Vor Bio to Present Clinical Data from First Patient Treated with Trem-cel at 2023 Tandem Meetings
Details : VOR33 (trem-cel) is our lead eHSC product candidate created by genetically modifying healthy donor HSCs in order to remove the CD33 surface target which is involved in causing AML and other blood related cancers thus, protecting them from a targeted ther...
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VOR33 (Engineered Hematopoietic Stem Cell) is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell therapy product that lacks the CD33 myeloid protein.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The pre-clinical data of VOR33 (Engineered Hematopoietic Stem Cell), demonstrates that multiplex deletion by CRISPR/Cas9 of CD33 and CLL-1 from human CD34+ HSPCs maintained cell function and persisted long-term post engraftment in vivo.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : VOR33,Ozogamicin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable